Previous Article | Next Article ![]()
Infection and Immunity, June 2001, p. 3737-3743, Vol. 69, No. 6
Department of Medicine, Division of
Rheumatology/Immunology, New England Medical Center and Tufts
University School of Medicine, Boston, Massachusetts 02111
Received 3 January 2001/Returned for modification 1 March
2001/Accepted 26 March 2001
Lyme arthritis is the most common complication following infection
of human individuals with Borrelia burgdorferi sensu
stricto. In mice, B. burgdorferi infection leads to
arthritis of the tibiotarsal joints. Arthritis severity in mice is
under host genetic control, as BALB/c mice developed mild arthritis but
C3H/He mice developed severe disease following B. burgdorferi infection. To study the role of gamma interferon
(IFN- Adaptive responses of T and B cells
function primarily to control Borrelia burgdorferi expansion
and only indirectly influence Lyme arthritis severity in the mouse. The
natural reservoir for B. burgdorferi in the northeastern
United States, Peromyscus leukopus, does not develop any
signs of Lyme infection (25). However, various laboratory
mice, including both immune-deficient and competent strains, developed
signs following tick transmission of or inoculation with B. burgdorferi (4, 5, 35). These signs
included periarticular edema, arthritis, and carditis. Arthritis
severity is under host genetic control (45).
C57BL/6J mice were very arthritis resistant, BALB/cJ (BALB/c) mice
developed mild arthritis, and C3H/HeJ (C3H) mice developed severe
arthritis (4, 5). The magnitudes and types of immune
responses elicited were important determinants of disease pathogenesis.
BALB/c congenic immunodeficient C.B-17-scid and
C3H/HeSnSmn-scid mice developed severe arthritis, high
spirochete burdens in the joint, and Lyme carditis following infection,
demonstrating that adaptive antigen-specific T- and B-cell immune
responses are protective in BALB/c and C3H mice (8, 10,
35). It was first suggested that inflammatory Th1 responses were
pathogenic. C3H mice developed a Th1 immune response, and when this
response was switched by administration of anti-gamma interferon
(anti-IFN- Several independent studies have now demonstrated that
IFN- Mice.
129-ifngrtml
(IFN- B. burgdorferi infection.
Stephen Barthold (Yale
University, New Haven, Conn.) kindly provided the N40 isolate of
B. burgdorferi (7). Low-passage B. burgdorferi N40 organisms were frozen into single-experiment aliquots in Barbour-Stoenner-Kelly (BSK) II medium with 30% glycerol (Sigma Chemical Co., St. Louis, Mo.). Infections were performed as
described previously (13). Briefly, frozen B. burgdorferi was thawed rapidly, transferred into 10 volumes of BSK
II-medium, and cultured at 32°C overnight prior to the enumeration of
motile spirochetes by dark-field microscopy. Motility, a minimal
estimate of viability, was consistently greater than 75%. Five- to
6-week-old mice of an individual litter were divided into two groups.
Mice in the first group were inoculated in the right hind footpad with 2 × 104 motile spirochetes in 50 µl of BSK II
medium, and the remaining mice were mock infected with BSK II medium
alone. Fifteen litters of mice were used for the reported experiments.
Culture of B. burgdorferi from tissue.
Infection
was tested at the time of sacrifice by culture of ear punch biopsy
material, joint tissue, or peripheral blood in BSK II medium. Infection
was confirmed for a majority of B. burgdorferi-infected mice
(range, 70 to 90%) in each experiment. Contaminated cultures were
discarded and thus infection status was not confirmed by culture for
some animals. Spirochetes from joint cultures were counted on culture
day 7 using a Petroff-Hausser counting chamber (C. A. Hausser & Son, Philadelphia, Pa.). The initial number of spirochetes in the joint
was extrapolated by comparison with counts from control 7-day cultures
inoculated initially with 10-fold serially diluted (107 to
102) live spirochetes (23). Negative cultures
were reexamined on days 10, 14, and 21.
Ankle measurement and histopathology.
Tibiotarsal joints
were measured on a weekly basis with a spring-loaded microcaliper
(Federal, Providence, R.I.). Tibiotarsal joints were surgically removed
from infected mice after sacrifice and immediately fixed in 10%
formalin (Sigma Chemical Co.). Thin section slides from decalcified and
paraffin-embedded joints were prepared and stained with hematoxylin and
eosin in the Department of Pathology, Tufts University School of
Veterinary Medicine (Grafton, Mass.). Slides were numbered sequentially
as sections were made, and this coding system was maintained until
after the scoring was completed. Sections were examined microscopically
for infiltrating cells and morphology. Based primarily on the amount of
mononuclear cell infiltrate in synovium but also on other signs of
arthritis, including synovial hypertrophy, tendonitis, and cartilage
thickening, an integer score of 0 (no infiltrating cells were
observed), 1 (one or several small and discrete areas of infiltrate), 2 (multiple infiltrates without other gross changes), or 3 (heavy
contiguous infiltrates in joints, tendons, and muscle) was subjectively
assigned to each sample. Each slide was scored by two investigators
(J.D. and L.G.) independently, and the final score for each sample was the average of the two. If the independent scores for a given sample
differed by more than one, both investigators reexamined the slide and
one or both changed their scores to reduce the difference to one. Only
six slides (6%) had to be rescored in this way. After all scoring and
reconciliation was completed, a third investigator (M.E.) uncoded the
results and calculated the group means. Data from culture-negative and
unconfirmed mice in the infected group have been included in the
figures and tables of the present paper.
Preparation of B. burgdorferi antigen.
B.
burgdorferi soluble antigen was prepared from a 500-ml culture of
spirochetes (109 spirochetes/ml). After centrifugation for
20 min at 15°C at 12,000 × g (10,000 rpm in an SS-34
rotor), the spirochete pellet was resuspended in 5 ml of
phosphate-buffered saline (PBS) with Mg2 (Sigma Chemical
Co.). The suspension was sonicated three times for 2 min each time
(at 15-second intervals), on ice, at a cycle level of 50% on a
Sonifier 450 (Branson Sonic Power Company, Danbury, Conn.). The
sonicate was centrifuged again as described above and the supernatant
of soluble antigens was removed and stored in aliquots at Antigen-specific recall response in vitro.
Draining lymph
nodes were harvested from mice 10 to 14 days postinfection, at the
onset of measurable arthritis (Fig. 1). Irradiated spleen cells (1,700 to 2,200 rad; 107 cells/ml)
from mock-infected syngeneic mice were pulsed with B. burgdorferi soluble antigen (final concentration, 35 µl/ml) for
60 min and washed twice with complete RPMI medium (RPMI 1640 with 10%
heat-inactivated fetal calf serum [Sigma Chemical Co.], 20 mM HEPES,
1 mM sodium pyruvate, a 1× concentration of nonessential amino acids,
2 mM L-glutamine, and 20 µg of gentamicin per ml [all
constituents were obtained from BioWhittaker, Walkersville, Md.])
before use as antigen-presenting cells. Single-cell suspensions from
pooled lymph nodes were washed twice with complete RPMI medium and
plated at 5 × 105 cells/well in 96-well plates in the
presence or absence of 106 antigen-pulsed irradiated
antigen-presenting cells. After 4 to 10 days of in vitro restimulation,
cells were activated for the final 5 h of culture with soluble
anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) in the presence of 3 µM monensin (Sigma Chemical Co.) to retard cytokine export from the
Golgi body.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3737-3743.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Gamma Interferon Is Not Required for Arthritis
Resistance in the Murine Lyme Disease Model
and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) in arthritogenesis, targeted mutant mice lacking the IFN-
receptor (IFN-
R) were infected by inoculation with B. burgdorferi. IFN-
R
/
and parental 129/SvEv mice
developed mild arthritis of similar severity, as determined both by
weekly tibiotarsal joint measurements and histopathology at 2 and 5 weeks postinfection. Both strains of mice had the same spirochetal
burden in the joints, suggesting that the IFN-
R
/
mice were not impaired in controlling spirochetal expansion in vivo.
The wild-type mice mounted a Th1 response, with a predominance of
CD4+ IFN-
+ T cells observed by flow
cytometry. In contrast, the IFN-
R
/
mice mounted a
Th2 response, with a predominance of CD4+ IL-4+
T cells. As expected given their cytokine profile, the
IFN-
R
/
mice produced fewer CD8+
IFN-
+ and MAC-1+ IL-12+ cells
and less immunoglobulin G2a (IgG2a) than their wild-type counterparts.
These results strongly suggest that IFN-
is not required for
arthritis resistance or as part of an effective immune response against
B. burgdorferi.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) antibody, the spirochete burdens and disease severity
were significantly reduced (22, 30). However,
administration of anti-interleukin-12 (anti-IL-12) to C3H mice in doses
that significantly suppressed IFN-
production only slightly reduced
acute arthritis and had little or no effect on joint edema
(1). Spirochete burdens were significantly higher in the
anti-IL-12-treated mice, suggesting that blockade of IL-12 weakened
spirochete control by the immune system. Targeted mutant C3H
IFN-
/
mice remained susceptible to severe arthritis
(9). The majority of evidence for C3H mice suggests that
IFN-
is not responsible for arthritis susceptibility. In BALB/c mice
arthritis resistance was linked to development of a Th2 immune response
(22, 30). However, a protective function for IFN-
in
resistant mice was not ruled out.
R
/
mice are immune competent and able to mount
inflammatory immune responses in both the experimental allergic
encephalomyelitis and collagen-induced arthritis models (19,
28, 34, 44, 46). IFN-
R
/
mice were more
susceptible to Leishmania major (41). In
contrast, our results demonstrate that IFN-
R
/
mice
were able to control spirochete expansion as efficiently as their
wild-type counterparts, with no change in arthritis resistance, in the
context of a switch to a predominant Th2 response.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
R
/
) mice (19) and wild-type
control 129/SvEv mice were provided by Michel Aguet (Institute of
Molecular Biology I, University of Zurich, Zurich, Switzerland), and
mice were bred and housed in the barrier containment facility (BL-3) of
the Division of Laboratory Animal Medicine, New England Medical Center,
Boston, Mass. It is important to note that the 129/SvEv mice were not the contaminated, inbred, commercially available, 129/SvEvTac mice
(36). BALB/cJ and C3H/HeJ mice were obtained from the
Jackson Laboratory. All experimental protocols involving mice were
reviewed and approved by the Institutional Review Board of the New
England Medical Center.
70°C
after being filtered through a 0.45-µm-pore-size filter (Millipore,
Bedford, Mass.).

View larger version (18K):
[in a new window]
FIG. 1.
Tibiotarsal joint diameters. IFN-
R
/
(RKO) mice developed arthritis similar to that of 129/SvEv mice
following B. burgdorferi infection. Tibiotarsal joints of
129/SvEv and IFN-
R
/
mice were measured with calipers
at weekly intervals after infection with B. burgdorferi (i)
or injection with BSK II media. Each data point represents the mean sum
of diameters for right and left hind joints for a minimum of 5, to a
maximum of 24, mice (males and females). Standard deviations were
greater for infected (0.02 to 0.03 mm) than for mock-infected (0.01 to
0.02 mm) mice (data not shown). IFN-
R
/
mice showed
a significantly greater mean increase in diameter compared to
129/SvEv mice at day 7 only (P < 0.002). The infected
mice showed significantly greater mean increases in diameter than
the control mice for both strains on days 14 (P < 0.0004 for 129/SvEv mice; P < 0.0001 for
IFN-
R
/
mice), 21 (P < 0.0002 for
129/SvEv mice; P < 0.0001 for
IFN-
R
/
mice), 28 (P < 0.03 for
129/SvEv mice; P < 0.008 for IFN-
R
/
mice), and 35 (P < 0.003 for 129/SvEv mice;
P < 0.0001 for IFN-
R
/
mice), but
not day 7.
Antibodies.
Flow cytometry staining buffer I (FSB-I)
consisted of PBS (BioWhittaker) with 1% heat-inactivated fetal calf
serum (Sigma Chemical Co.) and 0.1% NaN3 (Sigma Chemical
Co.), and FSB-II was PBS with 1% heat-inactivated fetal calf serum and
0.1% saponin (Sigma Chemical Co.). Cychrome-anti-CD4 (RM4-5) (working
dilution, 1:100 in FSB-I), cychrome-anti-CD8 (53-6.7) (working
dilution, 1:100 in FSB-I), phycoerythrin (PE)-anti-IL-4 (11B11)
(working dilution, 1:50 in FSB-II), fluorescein isothiocyanate
(FITC)-anti-IFN-
(R4 6A2) (working dilution, 1:200 in FSB-II),
PE-anti-IL-10 (JES5-16E3) (working dilution, 1:50 in FSB-II),
PE-anti-IL-12 (C15.6) (working dilution, 1:50 in FSB-II),
PE-anti-tumor necrosis factor alpha (TNF-
) (MP6-XT22) (working
dilution, 1:50 in FSB-II), anti-CD3 (145.2C11), anti-CD28 (37.51), and
Fc block (anti-CD16/32 [2.4G2]) were all purchased from
PharMingen (San Diego, Calif.). FITC-anti-CD11b (MAC-1)
(working dilution, 1:100 in FSB-I) was kindly provided by Henry Wortis
(Tufts University School of Medicine, Boston, Mass.).
Intracellular cytokine analysis by flow cytometry. Cells were washed in FSB-I and incubated for 5 min with Fc block at 4°C. These cells were then stained conventionally for cell surface markers (cychrome-anti-CD4, Cychrome-anti-CD8, and FITC-anti-MAC-1) and fixed in 4% paraformaldehyde (Sigma Chemical Co.) in PBS for 20 min. Fixed cells were washed and permeabilized with FSB-II and then stained with anti-cytokine antibodies. Cells stained in this manner were analyzed on a FACScan apparatus using LYSIS II software (Becton Dickinson, San Jose, Calif.). An analysis gate was limited to large activated blasts.
B. burgdorferi antigen-specific enzyme-linked immunosorbent assay (ELISA). Flat-bottom microplates (96-well Immulon no. 1 plate; Dynatech Laboratories, Chantilly, Va.) were coated with 5 µg of soluble B. burgdorferi antigen sonicate per ml in coating buffer (50 mM sodium bicarbonate [Sigma Chemical Co.], 2 mM NaN3 [pH 9.6]) overnight at 4°C and then blocked with blocking buffer (PBS, 0.05% Tween 20 [Bio-Rad, Hercules, Calif.], 5% dried nonfat milk [pH 7.6; SACO Foods, Inc., Middleton, Wis.]) for 45 min at 37°C. Serum samples from individual mice were serially diluted with blocking buffer and incubated in the antigen-coated plates for 45 min at 37°C. Plates were washed with rinse buffer (PBS with 0.05% Tween 20). Alkaline phosphatase-conjugated goat anti-mouse immunoglobulin M (IgM), IgG, IgG1, or IgG2a (all from Southern Biotechnology Associates, Birmingham, Ala.) were diluted 1:1,000 with blocking buffer and used as secondary antibodies; plates were incubated and washed as described above. Two hundred microliters of a solution containing 1-mg/ml pNpp and 8 µM ZnCl2 dissolved in alkaline buffer (0.1 M glycine, 1 mM MgCl2, 3 mM NaN3, [pH 10.5]; all reagents from Sigma Chemical Co.) were added to each well of the microtiter plate and incubated at 37°C for 1 to 5 min. Microplates were read with a microplate reader (model 550; Bio-Rad) at 405 nm. Titer was calculated by extrapolation from the linear regression of the absorbance from the 1:400, 1:2,000, and 1:10,000 dilutions of each serum sample. The titer was defined as the point where this line crossed that of the mean plus three standard deviations of a pool of negative control sera.
Statistical analysis. Means of groups were compared using Student's t test (29). Probability (P) values that were less than or equal to 0.05 were considered significant.
| |
RESULTS |
|---|
|
|
|---|
Absence of the IFN-
receptor (IFN-
R) did not change
arthritis.
Mice were infected with B. burgdorferi sensu
stricto and monitored for development of arthritis by weekly
tibiotarsal joint measurements, and histopathological examination of
joint tissue from mice sacrificed at 2 and 5 weeks postinfection.
Increases in tibiotarsal joint diameter have been correlated with
severe arthritis, although they do not directly demonstrate joint
changes and primarily indicate edema and swelling of the tissues
surrounding the joint itself (1, 22). Infected mice of
both the IFN-
R
/
and parental 129/SvEv strains had
significantly more arthritis than control mice, as indicated by the
tibiotarsal diameters measured on days 14, 21, 28, and 35 and the
arthritis scores for day 14 (129 only) and day 35 (Fig. 1; Table
1). The IFN-
R
/
mice
developed measurable arthritis slightly faster than the 129/SvEv mice
(at day 7), suggesting that IFN-
or downstream effectors may have
enhanced early immunity (Fig. 1). Overall, IFN-
R
/
mice developed arthritis of equal maximum severity as the parental 129/SvEv strain (Fig. 1). The arthritis in these strains was comparable to that observed in BALB/c mice but less severe than that seen in C3H
mice (Fig. 1). Histopathological examination of joint tissue also
demonstrated no significant difference between arthritis in the
IFN-
R
/
mice and that in the 129/SvEv mice at either
2 or 5 weeks postinfection (Table 1).
|
IFN-
R
/
mice controlled spirochete growth.
Joints of infected mice were inoculated into BSK II medium at 2 weeks
postinfection. Serial dilutions of spirochetes of known concentrations
were inoculated into BSK II medium in parallel with the joint cultures.
Cultures were checked on days 7 and 10, and viable (motile) spirochetes
were counted. The number of spirochetes in the joints on day 0 was
extrapolated from a standard curve prepared from the spirochete counts
from the serially diluted cultures. There was no significant difference
between the spirochete burden from the 129/SvEv (3.34 ± 0.27 log10 spirochetes/joint; n = 5) and
IFN-
R
/
(3.26 ± 0.08 log10
spirochetes/joint; n = 7) mice (Table
2). The
IFN-
R
/
mice controlled growth of organisms in the
joints as well as wild-type mice.
|
Th2 response made by IFN-
R
/
mice.
It has
been recognized for some time that naive CD4+ T cells
differentiate upon activation into inflammatory (Th1) or helper (Th2)
effectors. In experiments in which anti-IFN-
reduced arthritis severity in C3H mice, this treatment also switched the immune response
to a Th2 profile, defined as enhanced production of IL-4 (22). Arthritis resistance has been associated with Th2
effectors late in disease (21), as well as with high
innate inflammatory responses and Th1 cells early in disease (13,
21, 51). The Th response phenotype was defined by determining
the relative abundance of antigen-specific effector cells producing
IL-4 (Th2) or IFN-
(Th1). The draining lymph nodes were removed from
mice 10 to 14 days postinfection, at the peak of the primary immune response, and the mononuclear cells were restimulated in vitro for 4 to
10 days with soluble B. burgdorferi antigen-pulsed
irradiated syngeneic spleen cells as antigen-presenting cells. Few
cells from mock-infected mice survived and proliferated under these conditions (data not shown). The T cells were then stimulated to
produce and accumulate intracellular cytokine with a short, 5-h pulse
with anti-CD3 and anti-CD28 in the presence of monensin, as described
previously (13). These cells were then subjected to flow
cytometry for the surface T-cell (CD4 or CD8) or macrophage (MAC-1)
phenotype, and intracellular cytokine production (IL-4, IFN-
, IL-10,
TNF-
, IL-12). Analysis of CD4+ T cells showed clear
evidence that, while the 129/SvEv mice produced a predominant Th1
response, the IFN-
R
/
mice produced a predominant Th2
response (Fig. 2). Loss
of the IFN-
R enhanced production of IL-4, which was likely
responsible for the diminished production of IFN-
(Fig. 2). The
skewed pattern was present after 4 days of culture, the earliest time
point tested (Fig. 2B).
|
R
/
mice, it was possible that other cell types,
such as CD8+ T cells or macrophages, were present and
producing cytokines characteristic of a Th1 response. The 129/SvEv mice
had significantly more CD8+ IFN-
+ T cells
than the IFN-
R
/
animals (Fig.
3). Macrophages, including those
producing IL-12, were present in small numbers but were more frequent
in the 129/SvEv mice (Fig. 3). Taken together with the CD4 results,
these criteria suggest that the IFN-
R
/
mice
generated a Th2 rather than a Th1 response to infection with B. burgdorferi. Both Th responses were associated with arthritis resistance.
|
Anti-B. burgdorferi IgG2a production impaired in
IFN-
R
/
mice.
A final criterion for determining
the predominance of the Th1 phenotype is the functional effect of the
CD4+ effectors on antibody production. Class switching in
the mouse, in particular, production of IgG2a, is dependent in part on
IFN-
(37). At 2 weeks postinfection, both strains of
mice produced equivalent amounts of B. burgdorferi-specific
IgM, and IgG levels were generally below the limit of detection of our
ELISA assay (data not shown). We therefore examined the B. burgdorferi specific immunoglobulin in serum in both mouse strains
5 weeks postinfection. As predicted by their genetic deficit, many
IFN-
R
/
mice had impaired production of IgG2a
compared to the 129/SvEv mice (Fig. 4). Consistent with the apparent
enhancement of IL-4 producing CD4+ Th cells in these mice
(Fig. 2), there was a slight increase in the IgG1 titers. Total IgG
titers were diminished in some animals (Fig.
4). This suggests that the
IFN-
R
/
mice generated a weak Th2 immune response.
|
Production of IL-10 and TNF-
equivalent in both mouse
strains.
One of the major proinflammatory cytokines associated
with arthritis in murine models and in human disease is TNF-
(20, 27, 32, 42, 47, 48). A large number of
TNF-
+ cells, of which most were CD4+
TNF-
+ T cells, were identified in B. burgdorferi-stimulated cultures from infected mice of both strains
(Table 2). In fact, a number of dual producing cells was observed.
TNF-
production was observed in restimulated cultures from
mock-infected IFN-
R
/
mice; values were slightly
lower than those observed in cultures from infected mice. We also noted
a similar number of IL-10+ cells in both 129/SvEv (10.9%)
and IFN-
R
/
(11.3%) mouse strains, irrespective of
the underlying Th response. IL-10 production was absent in restimulated
cultures of mock infected 129/SvEv mice (1.1%). IL-10 generally has a
strong inhibitory effect on Th1 cells and macrophages (15, 18,
26, 33).
| |
DISCUSSION |
|---|
|
|
|---|
Transmission of B. burgdorferi to humans by infected
Ixodes ricinus complex ticks leads to a range of symptoms,
from self-resolving erythema migrans with no sequelae to antibiotic
treatment-resistant Lyme arthritis (39, 40). The observed
variation reflects both differences in pathogen (12, 43)
and differences in host susceptibility to infection and pathogenesis.
For example, although even patients who developed severe destructive
Lyme arthritis usually responded to antibiotic treatment, up to 10% of
such patients had arthritis which continued for more than 3 months
following 2 months of oral antibiotics and/or 1 month of
intravenous antibiotic therapy (40). Some of these
individuals were shown to possess a major histocompatibility complex molecule, DRB1*0401 (38), which was capable of
presenting both a peptide of B. burgdorferi OspA and a
cross-reactive self-peptide, human LFA-1
332-340
(16). DRB1*0401-positive individuals were thus at
risk for developing a more severe disease course. Other risk factors
for Lyme arthritis remain to be identified.
Arthritis has been associated with a proinflammatory cytokine milieu (49, 50). In a study of patients with Lyme arthritis, the Th1 to Th2 ratio correlated directly with arthritis severity, such that the higher the ratio, the greater the joint swelling (17). On the other hand, inflammatory immune responses were shown to be important for controlling infection, as demonstrated in the murine Lyme disease model. For example, genetically resistant mice with the beige mutation, which limits cell-mediated immunity, developed severe arthritis following B. burgdorferi infection (6). For C57BL/6 and DBA/2 strains, arthritis resistance was shown to be under the control of the innate immune system and independent of spirochete control by T and B cells (10). In C3H mice, in contrast, both innate and acquired immune responses failed to control spirochetes and mice developed severe disease (8, 10). BALB/c mice were shown to be unique in that their innate immune systems failed to control spirochetes, but they generated a robust T- and B-cell-mediated response. Thus the genetically related C.B-17 mice were inherently arthritis susceptible, as seen for C.B-17-scid mice, but T and B cells controlled spirochete expansion, carditis, and arthritis except in cases of extreme challenge (8, 10, 35). In BALB/c mice, arthritis resolution, but not carditis resolution or reduced spirochetemia, was induced by a humoral response to the B. burgdorferi arthritis-resolving protein (Arp) (14).
IFN-
is produced by T cells and affects both T cells and
macrophages. The role of IFN-
in Lyme disease has been studied extensively in C3H mice, in which it was initially thought that pathogenic Th1 responses contributed to arthritis (22,
30). However, elimination of IFN-
at the gene level in C3H
mice had no effect on B. burgdorferi burden or arthritis
severity (9). This ruled out a requirement for IFN-
in
pathogenesis. In fact the preponderance of evidence suggests that
inflammatory responses are protective in mice infected with
B. burgdorferi. In C3H-scid mice, blocking
antibodies directed against the proinflammatory cytokine IL-12 limited
innate responses, reduced spirochete control, and exacerbated arthritis
severity (2). BALB/c mice generated a larger early Th1
response, and this correlated with arthritis resistance (21,
51).
Until the present study was undertaken, the role of IFN-
had not yet
been studied in genetically arthritis-resistant mice (9,
22), which left open the possibility of a protective role for
this cytokine. In the present study, IFN-
R
/
mice had
no gross defect in spirochete control, as determined by culture of
organisms from joints of infected mice. This argues against a
requirement for IFN-
in immunity to B. burgdorferi in
genetically arthritis-resistant mice. Loss of function also did not
change arthritis susceptibility. This demonstrates that there is no
protective requirement for IFN-
in the murine Lyme disease model.
B. burgdorferi soluble antigens activated a large number of
TNF-
-producing T cells in the 129/SvEv and IFN-
R
/
mice; TNF-
might have promoted arthritis in the presence and absence of IFN-
(20, 27, 32, 42, 47, 48). In addition, a large number of IL-10-producing T cells were activated by
B. burgdorferi antigen. Elimination of IL-10 in
genetically resistant C57BL/6 mice enhanced spirochete control but
nonetheless exacerbated arthritis (11). In vitro studies
of human synovial infiltrating leukocytes showed that IL-10 suppressed
production of inflammatory cytokines and possibly functionally
inhibited synovial fluid macrophages (18). IL-10 may be
produced as an anti-inflammatory cytokine (15, 18, 26) in
a negative feedback response to TNF-
or other proinflammatory
molecules. IL-10 has also been implicated in disregulated autoimmunity
(3, 24, 31, 33).
In the murine L. major model, IFN-
R
/
mice
were more susceptible to infection than wild-type mice, but they did
not switch from a Th1 to Th2 immune response (41).
However, in the present system dominance clearly changed from a Th1 to
a Th2 response, using the criteria of cytokine production, accessory
cell activation, and immunoglobulin isotype. The production of
T-cell-derived IL-4 and IFN-
was more dramatically affected than the
B-cell response. These data demonstrate that the type of Th response is
not related to genetic arthritis resistance in the 129/SvEv mice.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by grants from the Harold G. and Leila Y. Mathers Foundation (to L.G.) and National Institutes of Health training grant AR07570 (to J.Z.D.).
We thank Joseph Aroy for initial consultation on the histopathology and Allen Steere and Brigitte Huber for support and discussions.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: New England Medical Center, Division of Rheumatology, Box 406, 750 Washington St., Boston, MA 02111. Phone: (617) 636-8527. Fax: (617) 636-4252. E-mail: lglickstein{at}lifespan.org.
Present address: Mediplex Rehabilitation Hospital, New Bedford, MA 02745.
Present address: BD PharMingen, San Diego, CA 92121.
Editor: E. I. Tuomanen
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anguita, J., D. H. Persing, M. Rincon, S. W. Barthold, and E. Fikrig. 1996. Effect of anti-interleukin 12 treatment on murine Lyme borreliosis. J. Clin. Investig. 97:1028-1034[Medline]. |
| 2. | Anguita, J., S. Samanta, S. W. Barthold, and E. Fikrig. 1997. Ablation of interleukin-12 exacerbates Lyme arthritis in SCID mice. Infect Immun. 65:4334-4336[Abstract]. |
| 3. | Balasa, B., and N. Sarvetnick. 1996. The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. J. Autoimmun. 9:283-286[CrossRef][Medline]. |
| 4. | Barthold, S. W. 1996. Lyme borreliosis in the laboratory mouse. J. Spir. Tick-borne Dis. 3:22-44. |
| 5. | Barthold, S. W., D. S. Beck, G. M. Hansen, G. A. Terwilliger, and K. D. Moody. 1990. Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 162:133-138[Medline]. |
| 6. | Barthold, S. W., and M. de Souza. 1995. Exacerbation of Lyme arthritis in beige mice. J. Infect. Dis. 172:778-784[Medline]. |
| 7. | Barthold, S. W., M. S. de Souza, J. L. Janotka, A. L. Smith, and D. H. Persing. 1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143:959-971[Abstract]. |
| 8. | Barthold, S. W., C. L. Sidman, and A. L. Smith. 1992. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am. J. Trop. Med. Hyg. 47:605-613. |
| 9. |
Brown, C. R., and S. L. Reiner.
1999.
Experimental Lyme arthritis in the absence of interleukin-4 or gamma interferon.
Infect. Immun.
67:3329-3333 |
| 10. |
Brown, C. R., and S. L. Reiner.
1999.
Genetic control of experimental Lyme arthritis in the absence of specific immunity.
Infect. Immun.
67:1967-1973 |
| 11. |
Brown, J. P.,
J. F. Zachary,
C. Teuscher,
J. J. Weis, and R. M. Wooten.
1999.
Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense.
Infect. Immun.
67:5142-5150 |
| 12. | Canica, M. M., F. Nato, L. du Merle, J. C. Mazie, G. Baranton, and D. Postic. 1993. Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis. Scand. J. Infect. Dis. 25:441-448[Medline]. |
| 13. | Dong, Z., M. D. Edelstein, and L. J. Glickstein. 1997. CD8+ T cells are activated during the early Th1 and Th2 immune responses in a murine Lyme disease model. Infect. Immun. 65:5334-5337[Abstract]. |
| 14. |
Feng, S.,
E. Hodzic, and S. W. Barthold.
2000.
Lyme arthritis resolution with antiserum to a 37-kilodalton Borrelia burgdorferi protein.
Infect Immun.
68:4169-4173 |
| 15. | Flores-Villanueva, P. O., X. X. Zheng, T. B. Strom, and M. J. Stadecker. 1996. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensistivity reactions and egg granuloma formation in schistosomiasis. J. Immunol. 156:3315-3320[Abstract]. |
| 16. |
Gross, D. M.,
T. Forsthuber,
M. Tary-Lehmann,
C. Etling,
K. Ito,
Z. A. Nagy,
J. A. Field,
A. C. Steere, and B. T. Huber.
1998.
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.
Science
281:703-706 |
| 17. |
Gross, D. M.,
A. C. Steere, and B. T. Huber.
1998.
T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis.
J. Immunol.
160:1022-1028 |
| 18. | Hart, P. H., M. J. Ahern, M. D. Smith, and J. J. Finlay-Jones. 1995. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 84:536-542[Medline]. |
| 19. |
Huang, S.,
W. Hendriks,
A. Althage,
S. Hemmi,
H. Bluethmann,
R. Kamijo,
J. Vilcek,
R. M. Zinkernagel, and M. Aguet.
1993.
Immune response in mice that lack the interferon-gamma receptor.
Science
259:1742-1745 |
| 20. | Joosten, L. A., M. M. Helsen, F. A. van de Loo, and W. B. van den Berg. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39:797-809[Medline]. |
| 21. | Kang, I., S. W. Barthold, D. H. Persing, and L. K. Bockenstedt. 1997. T-helper-cell cytokines in the early evolution of murine Lyme arthritis. Infect. Immun. 65:3107-3111[Abstract]. |
| 22. | Keane-Myers, A., and S. P. Nickell. 1995. Role of IL-4 and IFN-gamma in modulation of immunity to Borrelia burgdorferi in mice. J. Immunol. 155:2020-2028[Abstract]. |
| 23. | Keane-Myers, A., and S. P. Nickell. 1995. T cell subset-dependent modulation of immunity to Borrelia burgdorferi in mice. J. Immunol. 154:1770-1776[Abstract]. |
| 24. |
Lee, M. S.,
R. Mueller,
L. S. Wicker,
L. B. Peterson, and N. Sarvetnick.
1996.
IL-10 is necessary and sufficient for autoimmune diabetes in conjuction with NOD MHC homozygosity.
J. Exp. Med.
183:2663-2668 |
| 25. | Levine, J. F., M. L. Wilson, and A. Spielman. 1985. Mice as reservoirs of the Lyme disease spirochete. Am. J. Trop. Med. Hyg. 34:355-360. |
| 26. | Li, L., J. F. Elliott, and T. R. Mosmann. 1994. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. 153:3967-3978[Abstract]. |
| 27. | Maini, R. N., M. J. Elliott, F. M. Brennan, R. O. Williams, C. Q. Chu, E. Paleolog, P. J. Charles, P. C. Taylor, and M. Feldmann. 1995. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144:195-223[CrossRef][Medline]. |
| 28. | Manoury-Schwartz, B., G. Chiocchia, N. Bessis, O. Abehsira-Amar, F. Batteux, S. Muller, S. Huang, M. C. Boissier, and C. Fournier. 1997. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 158:5501-5506[Abstract]. |
| 29. | Matthews, D. E., and V. T. Farewell. 1988. Using and understanding medical statistics. Karger, Basel, Switzerland. |
| 30. |
Matyniak, J. E., and S. L. Reiner.
1995.
T helper phenotype and genetic susceptibility in experimental Lyme disease.
J. Exp. Med.
181:1251-1254 |
| 31. | Mueller, R., M. S. Lee, S. P. Sawyer, and N. Sarvetnick. 1996. Transgenic expression of interleukin 10 in the pancreas renders resistant mice susceptible to low dose streptozotocin-induced diabetes. J. Autoimmun. 9:151-158[CrossRef][Medline]. |
| 32. | Piguet, P. F., G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, and W. Lesslauer. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514[Medline]. |
| 33. |
Rennick, D. M.,
M. M. Fort, and N. J. Davidson.
1997.
Studies with IL-10 / mice: an overview.
J. Leukoc. Biol.
61:389-396[Abstract].
|
| 34. | Sandberg, J. O., B. Benda, N. Lycke, and O. Korsgren. 1997. Xenograft rejection of porcine islet-like cell clusters in normal, interferon-gamma, and interferon-gamma receptor deficient mice. Transplantation 63:1446-1452[CrossRef][Medline]. |
| 35. | Schaible, U. E., S. Gay, C. Museteanu, M. D. Kramer, G. Zimmer, K. Eichmann, U. Museteanu, and M. M. Simon. 1990. Lyme borreliosis in the severe combined immunodeficiency (SCID) mouse manifests predominantly in the joints, heart, and liver. Am. J. Pathol. 137:811-820[Abstract]. |
| 36. | Simpson, E. M., C. C. Linder, E. E. Sargent, M. T. Davisson, L. E. Mobraaten, and J. J. Sharp. 1997. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat. Genet. 16:19-27[CrossRef][Medline]. |
| 37. | Stavnezer, J. 1996. Immunoglobulin class switching. Curr. Opin. Immunol. 8:199-205[CrossRef][Medline]. |
| 38. | Steere, A. C., and L. A. Baxter-Lowe. 1998. Association of chronic, treatment-resistant Lyme arthritis with rheumatoid arthritis (RA) alleles. Arthritis Rheum. 41:S81[CrossRef]. |
| 39. | Steere, A. C., S. E. Malawista, D. R. Snydman, R. E. Shope, W. A. Andiman, M. R. Ross, and F. M. Steele. 1977. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 20:7-17[Medline]. |
| 40. | Steere, A. C., R. T. Schoen, and E. Taylor. 1987. The clinical evolution of Lyme arthritis. Ann. Intern. Med. 107:725-731. |
| 41. |
Swihart, K.,
U. Fruth,
N. Messmer,
K. Hug,
R. Behin,
S. Huang,
G. Del Giudice,
M. Aguet, and J. A. Louis.
1995.
Mice from a genetically resistant backround lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response.
J. Exp. Med.
181:961-971 |
| 42. |
Thorbecke, G. J.,
R. Shah,
C. H. Leu,
A. P. Kuruvilla,
A. M. Hardison, and M. A. Palladino.
1992.
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice.
Proc. Natl. Acad. Sci. USA
89:7375-7379 |
| 43. | van Dam, A. P., H. Kuiper, K. Vos, A. Widjojokusumo, B. M. de Jongh, L. Spanjaard, A. C. Ramselaar, M. D. Kramer, and J. Dankert. 1993. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17:708-717[Medline]. |
| 44. | Vermeire, K., H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys. 1997. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158:5507-5513[Abstract]. |
| 45. |
Weis, J. J.,
B. A. McCracken,
Y. Ma,
D. Fairbairn,
R. J. Roper,
T. B. Morrison,
J. H. Weis,
J. F. Zachary,
R. W. Doerge, and C. Teuscher.
1999.
Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease.
J. Immunol.
162:948-956 |
| 46. | Willenborg, D. O., S. Fordham, C. C. A. Bernard, W. B. Cowden, and I. A. Ramshaw. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune disease. J. Immunol. 157:3223-3227[Abstract]. |
| 47. |
Williams, R. O.,
M. Feldmann, and R. N. Maini.
1992.
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Proc. Natl. Acad. Sci. USA
89:9784-9788 |
| 48. |
Williams, R. O.,
L. J. Mason,
M. Feldmann, and R. N. Maini.
1994.
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.
Proc. Natl. Acad. Sci. USA
91:2762-2766 |
| 49. | Yin, Z., J. Braun, L. Neure, P. Wu, U. Eggens, A. Krause, T. Kamradt, and J. Sieper. 1997. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum. 40:69-79[Medline]. |
| 50. |
Yssel, H.,
M.-C. Shanafelt,
C. Soderberg,
P. V. Schneider,
J. Anzola, and G. Peltz.
1991.
Borrelia burgdorferi activates a T helper type I-like T cell subset in Lyme arthritis.
J. Exp. Med.
174:593-601 |
| 51. | Zeidner, N., M. L. Mbow, M. Dolan, R. Massung, E. Baca, and J. Piesman. 1997. Effects of Ixodes scapularis and Borrelia burgdorferi on modulation of the host immune response: induction of a TH2 cytokine response in Lyme disease-susceptible (C3H/HeJ) mice but not in disease-resistant (BALB/c) mice. Infect. Immun. 65:3100-3106[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||